Post-Marketing Requirement study to evaluate the safety of octaplas™ versus plasma in patients undergoing orthotopic liver transplantation with special emphasis on hyperfibrinolysisFirst published 22/01/2016 Last updated 16/03/2020 EU PAS number: EUPAS12164StudyFinalised